Jak se dívat na psychosomatiku

MUDr. Radkin Honzák, CSc.

Urol. praxi, 2015; 16(4)  

Retroperitoneal lymph node dissection as a treatment choice of testicular cancer

MUDr.David Hradil, MUDr.Milan Král, Ph.D., MUDr.Michal Grepl, Ph.D., doc.MUDr.Vladimír Študent, Ph.D.

Urol. praxi, 2015; 16(4): 144-147  

Non-seminoma germ cell tumor (NSGCT) represent 40–50 % of testicular cancer. Multinodal approach including combination of surveillance, chemotherapy and RPLND. Prior to the introduction of chemotherapy, RPLNP was the only treatment method following radical orchiectomy. Particularly due to the challenging nature nad numerus complications of classic open RPLND, adjutant therapy is the method of choice in non-seminoma testicular cancer. The introduction of a modified and nerve-sparing technice has reduced rate of intraoperative complications and significantly improves postoperative corse including ejaculatory dysfunction. Technically challenging...

Fosfomycin trometamol: re-established antibiotic in urology

MUDr.Miroslav Fajfr, Ph.D., MUDr.Miroslav Louda, Ph.D., MUDr.Pavla Paterová, MUDr.Lenka Ryšková, Ph.D.

Urol. praxi, 2015; 16(4): 148-150  

From October 2014 there has been available a „new“ per oral antibiotic for urinary tract infection in the Czech Republic - fosfomycin trometamol. This antibiotic, first described in 1969, is very effective to common urogenital pathogens include Gram positive cocci, but also to Gram negative bacteria with extended spectrum beta lactamase production. The study from Faculty hospital Hradec Králové confirms high susceptibility (78.9–97.0 %) of tested urological pathogens (Escherichia coli, Klebsiella pneumoniae, Proteus sp., Enterobacter sp.). But from the literature there is well known the rapid resistance increase after the...

Radionuclide therapy bone involvement in generalized prostate carcinoma

MUDr.Jozef Kubinyi, Ph.D., FEBNM, MUDr.Václav Ptáčník

Urol. praxi, 2015; 16(4): 152-153  

Prostatic carcinoma is one of the most frequent malignant diseases in man. Majority of complications and near all mortality is associated with metastatic and castration-resistant phase of prostate cancer (mCPRC). Except chemotherapy and targeted external radiotherapy it is possible to administer bone seeking beta or alpha emitters. In this short review authors present the possibilities and advantages of this therapy and its indications and contraindications.

Controversies in the hormonal treatment of castration-resistant prostate cancer

MUDr.Jana Katolická, Ph.D.

Urol. praxi, 2015; 16(4): 154-156  

Abiraterone and enzalutmide also led to an improved overal survival in docetaxel-treated patients with castration-resistant prostate cancer. Both have also been studied in chemotherapy –naive patients. Abiraterone and enzalutamide have less toxicity when compared to chemotherapeutic options. It is now clear that cross resistance is a potential therapeutic issue between hormonal agents.

Článek byl podpořen programem PRVOUK P37/04

MUDr.Miroslava Ryšánková

Urol. praxi, 2015; 16(4): 157-158  

Conservative treatment of urinary incontinence after radical prostatectomy Every patient who has undergone a radical prostatectomy, regardless of the approach, is potentially more or less risk for the development of urinary incontinence. This is a significant socioeconomic problem that affects the quality of life of the patient and his postoperative morbidity. The article was supported by program PRVOUK P37/04

Sexually transmitted infections and antimicrobial resistance in Neisseria gonorrhoeae

doc.MUDr.Ivana Kuklová, CSc., MUDr.Martina Kojanová, Ph.D., Mgr.Miroslava Slováčková

Urol. praxi, 2015; 16(4): 159-161  

The aim of this article is to provide an overview of sexually transmitted diseases and summarize the current legally binding regulations and guidelines of the Ministry of Health regarding the mandatory reporting, follow-up and contact tracing. Another aim is to provide information on up-to-date guidelines for gonorrhoea treatment, which may become a significant health concern due to the ability of Neisseria gonorrhoeae to develop resistance to antimicrobial therapies. Only one regimen, dual treatment with ceftriaxone and azithromycin, is recommended for treatment of gonorrhea worldwide.

Treatment of metastatic castration-resistant prostate cancer (mCRPC): abiraterone acetate as the first choice

MUDr.Michaela Matoušková, doc.MUDr.Miroslav Hanuš, CSc., Vlasta Králová

Urol. praxi, 2015; 16(4): 162-164  

Treatment options in the care of patients with malignant prostate tumours have expanded significantly in the recent years. Local therapy, whether surgical or radiation, and watchful waiting are suitable options for localized disease. Advanced diseases can no longer be cured, but in combination with local therapy, particularly radiation therapy, advanced tumours can be affected therapeutically by adding hormonal therapy. For generalized disease, systemic hormonal therapy is the treatment of choice. A response to hormonal therapy can be expected in more than 80% of patients with generalized disease. The duration of the response varies. The disease...

Malignant melanoma of the urethra

MUDr.Roman Šamudovský, MUDr.Jaroslav Všetička, Ph.D.

Urol. praxi, 2015; 16(4): 165-168  

69 year old patient , in the meantime without positive urological history, examination for asymptomatic hematuria at the urology clinic. On the basis of clinical, laboratory, and imaging was performed with flexible cystoscopy. In this investigation, we found urethral polyp, accompanied by urethral stenosis, because the patient is indicated for the optical urethrotomy and urethral polyp endoresection. The polyp was later verified histologically and immunohistochemically as malignant melanoma of the urethra. Primary malignant melanoma of the male urethra is very rare and the prognosis of this disease is poor. Subsequent CT examination of the...

Development of Crohn’s disease in ureteroileostomy in a patient ten years after radical cystectomy

MUDr.Pavel Elexa, MUDr.Jiří Král, MUDr.Jan Schraml, Ph.D., MUDr.Jiří Stehlík, MUDr.Martin Čegan, MUDr.Natálie Harmašová, MUDr.Monika Černá

Urol. praxi, 2015; 16(4): 170-171  

The article presents a case report of a female patient ten years after radical cystectomy for bladder cancer with a finding of a newly developed Crohn’s disease in an excluded loop of the terminal ileum in ureteroileostomy.

Neurogenic sarcoma of kidney

MUDr.Michal Přikryl

Urol. praxi, 2015; 16(4): 172-173  

Neurogenic sarcoma of kidney (malignant schwannoma) is a sporadic tumor with a poor prognosis. We present a case of a patient with this type of cancer.

Disinfection and sterilization of endoskopic instruments in urology

Mgr.Pavla Kordulová

Urol. praxi, 2015; 16(4): 174-177  

The text provides a comprehensive overview of the treatment of endoscopic instruments disinfection and sterilization in realition to the requirements of the Decree no. 306/2012.

aktualizaci rozšíříme přehled o další léčivé přípravky.

MUDr. Michaela Matoušková,, doc. MUDr. Miloš Broďák, Ph.D.,, Mgr. Veronika Črepová

Urol. praxi, 2015; 16(4): 182-186  

Urizia: komplexní léčba pro muže s LUTS již rok na českém trhu

MVDr. Pavel Macháček

Urol. praxi, 2015; 16(4): 178-180